Replies to post #47543 on Ayala Pharmaceuticals Inc (fka ADXS)

[zzaatt]

ADXS' generally poor reputation is also a factor (IMO),
as compared to some of the other companies (public and private)
who are pursuing neoantigen cancer vaccines.

I find that assertion rather puzzling!
What sort of "poor reputation" does ADXS have?
Is it based on poor performance of ADXS's science,
poor performance in the clinic, is it the low PPS?
And, what particular audience is it that has negative
feelings about the company? Is it other biotech executives,
is it BPs, perhaps biotech analysts?

I don't imagine there were polls taken, and other than
the gnashing of teeth that takes place on this board,
I'm not aware that there is some sort of public perception that
prevents the company from gaining recognition as it moves
forward with its technology.

Not least of the factors in attracting positive attention, is I would
think precisely that ADXS is operating in space a with tremendous
excitement and anticipation.

I would appreciate any further elucidation of the theory of
ADVS's "poor reputation".